The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis

Research output: Contribution to journal › Review › Research › peer-review

Standard

The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer : A Network Meta-Analysis. / Zhao, Yi; Wang, Wei; Liang, Hengrui; Yang, Chi-Fu Jeffrey; D'Amico, Thomas; Ng, Calvin S H; Liu, Chia-Chuan; Petersen, René Horsleben; Rocco, Gaetano; Brunelli, Alessandro; Liu, Jun; He, Jiaxi; Huang, Weizhe; Liang, Wenhua; He, Jianxing; AME Thoracic Surgery Collaborative Group.

In: The Annals of Thoracic Surgery, Vol. 107, No. 6, 2019, p. 1866-1875.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Zhao, Y, Wang, W, Liang, H, Yang, C-FJ, D'Amico, T, Ng, CSH, Liu, C-C, Petersen, RH, Rocco, G, Brunelli, A, Liu, J, He, J, Huang, W, Liang, W, He, J & AME Thoracic Surgery Collaborative Group 2019, 'The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis', The Annals of Thoracic Surgery, vol. 107, no. 6, pp. 1866-1875. https://doi.org/10.1016/j.athoracsur.2018.11.024

APA

Zhao, Y., Wang, W., Liang, H., Yang, C-F. J., D'Amico, T., Ng, C. S. H., Liu, C-C., Petersen, R. H., Rocco, G., Brunelli, A., Liu, J., He, J., Huang, W., Liang, W., He, J., & AME Thoracic Surgery Collaborative Group (2019). The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis. The Annals of Thoracic Surgery, 107(6), 1866-1875. https://doi.org/10.1016/j.athoracsur.2018.11.024

Vancouver

Zhao Y, Wang W, Liang H, Yang C-FJ, D'Amico T, Ng CSH et al. The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis. The Annals of Thoracic Surgery. 2019;107(6):1866-1875. https://doi.org/10.1016/j.athoracsur.2018.11.024

Author

Zhao, Yi ; Wang, Wei ; Liang, Hengrui ; Yang, Chi-Fu Jeffrey ; D'Amico, Thomas ; Ng, Calvin S H ; Liu, Chia-Chuan ; Petersen, René Horsleben ; Rocco, Gaetano ; Brunelli, Alessandro ; Liu, Jun ; He, Jiaxi ; Huang, Weizhe ; Liang, Wenhua ; He, Jianxing ; AME Thoracic Surgery Collaborative Group. / The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer : A Network Meta-Analysis. In: The Annals of Thoracic Surgery. 2019 ; Vol. 107, No. 6. pp. 1866-1875.

Bibtex

@article{309286c04fd543c6a3982c50c592e310,
title = "The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis",
abstract = "BACKGROUND: The optimal treatment for stage IIIA-N2 non-small cell lung cancer (NSCLC) is controversial. We aimed to address this important issue through a Bayesian network meta-analysis.METHODS: We performed a search of electronic databases for randomized controlled trials comparing the following treatments: surgery, radiotherapy, chemotherapy, and their multiple combinations before March 25, 2018. Pooled data on overall survival and treatment-related deaths were analyzed within the Bayesian framework.RESULTS: Eighteen eligible trials reporting 13 treatments were included. In terms of overall survival, neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy or radiotherapy, which tended to be consistent (hazard ratio [HR] 1.14, 95% credible interval [CrI] 0.21 to 5.93), ranked superior to other treatments. Notably, neoadjuvant chemotherapy followed by surgery and adjuvant radiotherapy was significantly more effective in prolonging survival than surgery alone (HR 0.38, 95% CrI 0.18 to 0.81), surgery plus adjuvant radiotherapy (HR 0.51, 95% CrI 0.29 to 0.92) and potentially surgery plus adjuvant chemotherapy (HR 0.49, 95% CrI 0.23 to 1.05). Overall, with 29% as the highest possibility of causing the fewest treatment-related deaths, neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy or radiotherapy was the safest treatment option.CONCLUSIONS: Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy or radiotherapy has the greatest possibility to be the optimal treatment with the best overall survival and fewest treatment-related deaths for stage IIIA-N2 NSCLC.",
author = "Yi Zhao and Wei Wang and Hengrui Liang and Yang, {Chi-Fu Jeffrey} and Thomas D'Amico and Ng, {Calvin S H} and Chia-Chuan Liu and Petersen, {Ren{\'e} Horsleben} and Gaetano Rocco and Alessandro Brunelli and Jun Liu and Jiaxi He and Weizhe Huang and Wenhua Liang and Jianxing He and {AME Thoracic Surgery Collaborative Group}",
note = "Copyright {\textcopyright} 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.",
year = "2019",
doi = "10.1016/j.athoracsur.2018.11.024",
language = "English",
volume = "107",
pages = "1866--1875",
journal = "The Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer

T2 - A Network Meta-Analysis

AU - Zhao, Yi

AU - Wang, Wei

AU - Liang, Hengrui

AU - Yang, Chi-Fu Jeffrey

AU - D'Amico, Thomas

AU - Ng, Calvin S H

AU - Liu, Chia-Chuan

AU - Petersen, René Horsleben

AU - Rocco, Gaetano

AU - Brunelli, Alessandro

AU - Liu, Jun

AU - He, Jiaxi

AU - Huang, Weizhe

AU - Liang, Wenhua

AU - He, Jianxing

AU - AME Thoracic Surgery Collaborative Group

N1 - Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

PY - 2019

Y1 - 2019

N2 - BACKGROUND: The optimal treatment for stage IIIA-N2 non-small cell lung cancer (NSCLC) is controversial. We aimed to address this important issue through a Bayesian network meta-analysis.METHODS: We performed a search of electronic databases for randomized controlled trials comparing the following treatments: surgery, radiotherapy, chemotherapy, and their multiple combinations before March 25, 2018. Pooled data on overall survival and treatment-related deaths were analyzed within the Bayesian framework.RESULTS: Eighteen eligible trials reporting 13 treatments were included. In terms of overall survival, neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy or radiotherapy, which tended to be consistent (hazard ratio [HR] 1.14, 95% credible interval [CrI] 0.21 to 5.93), ranked superior to other treatments. Notably, neoadjuvant chemotherapy followed by surgery and adjuvant radiotherapy was significantly more effective in prolonging survival than surgery alone (HR 0.38, 95% CrI 0.18 to 0.81), surgery plus adjuvant radiotherapy (HR 0.51, 95% CrI 0.29 to 0.92) and potentially surgery plus adjuvant chemotherapy (HR 0.49, 95% CrI 0.23 to 1.05). Overall, with 29% as the highest possibility of causing the fewest treatment-related deaths, neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy or radiotherapy was the safest treatment option.CONCLUSIONS: Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy or radiotherapy has the greatest possibility to be the optimal treatment with the best overall survival and fewest treatment-related deaths for stage IIIA-N2 NSCLC.

AB - BACKGROUND: The optimal treatment for stage IIIA-N2 non-small cell lung cancer (NSCLC) is controversial. We aimed to address this important issue through a Bayesian network meta-analysis.METHODS: We performed a search of electronic databases for randomized controlled trials comparing the following treatments: surgery, radiotherapy, chemotherapy, and their multiple combinations before March 25, 2018. Pooled data on overall survival and treatment-related deaths were analyzed within the Bayesian framework.RESULTS: Eighteen eligible trials reporting 13 treatments were included. In terms of overall survival, neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy or radiotherapy, which tended to be consistent (hazard ratio [HR] 1.14, 95% credible interval [CrI] 0.21 to 5.93), ranked superior to other treatments. Notably, neoadjuvant chemotherapy followed by surgery and adjuvant radiotherapy was significantly more effective in prolonging survival than surgery alone (HR 0.38, 95% CrI 0.18 to 0.81), surgery plus adjuvant radiotherapy (HR 0.51, 95% CrI 0.29 to 0.92) and potentially surgery plus adjuvant chemotherapy (HR 0.49, 95% CrI 0.23 to 1.05). Overall, with 29% as the highest possibility of causing the fewest treatment-related deaths, neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy or radiotherapy was the safest treatment option.CONCLUSIONS: Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy or radiotherapy has the greatest possibility to be the optimal treatment with the best overall survival and fewest treatment-related deaths for stage IIIA-N2 NSCLC.

U2 - 10.1016/j.athoracsur.2018.11.024

DO - 10.1016/j.athoracsur.2018.11.024

M3 - Review

C2 - 30557543

VL - 107

SP - 1866

EP - 1875

JO - The Annals of Thoracic Surgery

JF - The Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -

ID: 225120098